linjc16/ctgov huggingface dataset:
Predictors Of Mortality After Pelvic Fractures: A Retrospective Cohort Study From A Level-1 Trauma Center In Upper Egypt

Study Overview
=================
Brief Summary
-----------------
A retrospective cohort study was carried out for all pelvic fracture patients admitted to Assiut University Trauma Unit (AUTU), a level-1 trauma center. (AUTU) is located in Upper Egypt and provides healthcare to over 30,000 patients per year.

Detailed Description
-----------------
In 2010, a Pelvic Injury Registry was developed to document treatment and outcomes in a standardized manner. All patients admitted to AUTU sign an informed consent to permit using their data for research purposes. Patients' data are prospectively collected and stored in a local database specifically designed for this purpose. Data collected included age, gender, mechanism of injury, fracture classification, associated injuries, and admission to ICU, the length of hospital stay and presence of abdominopelvic collection as diagnosed by Focused Assessment with Sonography for Trauma (FAST) at admission. The primary outcome measure was in-hospital mortality. Predictors of in-hospital mortality were identified by comparing characters of survivors and non-survivors. Secondary objectives were to analyse the differences between adults and children and to analyse the causes and timing of death.

Official Title
-----------------
Predictors Of Mortality After Pelvic Fractures: A Retrospective Cohort Study From A Level-1 Trauma Center In Upper Egypt.

Conditions
-----------------
Registries, Pelvic Bone Injury, Morality

Intervention / Treatment
-----------------
* Other: The presence of a pelvic fracture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: first-time admissions and patients whose treatment was completed at our hospital all pelvic fracture patients admitted to our Trauma Unit. Exclusion Criteria: penetrating injuries isolated acetabular fractures Patients who were discharged on their own will against the medical advice or whose treatment was continued at another hospital re-admitted patients Firearm injuries
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Survivors<br>Patients whose pelvic fracture and survived till time of discharge from the hospital. | Other: The presence of a pelvic fracture<br> <br> |
| Non-Survivors<br>Patients whose pelvic fracture and died while in hospital. | Other: The presence of a pelvic fracture<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| in-hospital mortality | Death occurring while the patient is admitted in the hospital. | One month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pelvic fractures, mortality, predictors, trauma registry
Intracranial Hydatid Cyst

Study Overview
=================
Brief Summary
-----------------
Central nervous system (CNS) hydatid cysts is a rare presentation of hydatid cyst, although may be the cause of intracranial space-occupying lesions in 4% in endemic countries. It affects mostly children. The diagnosis of CNS hydatid is still problematic in spite of the advancements in imaging techniques (CT or MRI). Extirpation of the intact cyst is the treatment of choice, resulting in most cases to a complete recovery.

Detailed Description
-----------------
Hydatid disease is a parasitic induced disease caused by either Echinococcus granulosus or Echinococcus multilocularis during the larval stage of these tapeworms. Hydatid cysts are endemic in many countries, such as Latin America (Argentina, Brazil, Chile, Peru, and Uruguay); followed by Europe (France, Italy, and Greece), the Middle East (Turkey, Lebanon, Syria, and Jordan), Southeast Asia (China, Iran, and India) and Africa (Tunisia and less commonly, Egypt)

Official Title
-----------------
Intracranial Hydatid Cyst: Series of 8 Cases

Conditions
-----------------
Intracranial Neoplasm

Intervention / Treatment
-----------------
* Procedure: cyst extirpation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: intracranial hydatid cyst Exclusion Criteria: Arachnoid cysts conservative treatment

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: hydatid cyst<br> | Procedure: cyst extirpation<br>* complete removal of the cyst without rupture<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of patients who haven total removal of intracranial cyst | degree of consciousness incomplete extirpation without removal without neurological deficit 0 space | 7 years |
Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
Data regarding nivolumab as second line treatment in advanced non-small cell lung cancer (NSCLC) are based on selected populations and might not reflect daily practice. Investigators aimed at assessing efficacy and safety of nivolumab in a real-life setting and determining a subtype of NSCLC patients that are more likely to benefit from immunotherapy.

Official Title
-----------------
Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung Cancer: a French Observational Multicenter Study of 259 Patients (ABCT-IMMUNOBZH)

Conditions
-----------------
NSCLC

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: advanced NSCLC (stage IIIB-IV) failure of at least one line of chemotherapy. age ≥18 years, initiation of nivolumab between 01/09/2015 and 30/09/2016. Exclusion Criteria: nivolumab initiation after October 2016 prior involvement in an immunotherapy trial refusal to participate.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nivolumab Objective response rate | Objective response rate evaluated by RECIST 1.1 | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Real-life, nivolumab
Bone Mineral Density in Pediatric Epilepsy

Study Overview
=================
Brief Summary
-----------------
What are the effects of the currently used AEDs on bone mineralization in children and adolescents between the ages of 8 to 18? This is a pilot observational study using DEXA scans to measure bone mineral density in 100 patients The primary objective is to collect preliminary data on bone mineral density, body weight, dietary calcium intake, and activity level.

Official Title
-----------------
Bone Mineral Density in Pediatric Epilepsy: AED-Specific and Duration of Treatment-Specific Effects

Conditions
-----------------
Epilepsy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of generalized or partial seizures with or without generalization or a diagnosis of generalized seizures as defined in the International League Against Epilepsy Exclusion Criteria: steroid use chronic disease other than epilepsy

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma

Study Overview
=================
Brief Summary
-----------------
A large-scale, high-throughput, multi-dimensional comprehensive study of PDAC multiomics will be carried out. In this study, clinical specimens of resected PDAC collected by our research group from 2017 to 2019 will be selected as research objects.Tumor tissues and their adjacent non-tumor tissues from more than 200 PDAC patients are expected to be used for genome, transcriptome sequencing and mass spectrometry analysis of proteome and phosphorylated proteome.Combined with the data results of multiomics, bioinformatics analysis and network database information, we will clarify the relationship between multiomics of pancreatic cancer and established the new subtyping of pancreatic cancer proteome. A molecular landscape of the progression of pancreatic cancer at the genome-transcriptome-proteome level provides new therapeutic targets to improve the prognosis of this deadly disease.

Official Title
-----------------
Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma

Conditions
-----------------
Tumor Tissues and Non-tumor Tissues From PDAC Patients Were Used for Genomic and Transcriptome Sequencing Analysis and Proteomics and Phosphorylated Proteomics

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The diagnosis of pancreatic cancer was confirmed by histological examination or fine needle aspiration cytology; The tumor was graded according to THE WHO standard, and the tumor stage was graded according to the TNM stage; Exclusion Criteria: The inclusion criteria of the above groups were not met; There are few tissue specimens, only enough for clinical diagnosis; Patients are unwilling to conduct follow-up study; For the new diagnosed patient, radiotherapy or chemotherapy have been given in the previous three months;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention|No intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Integrative Proteomic Characterization of PDAC | The genome-transcriptome proteome level provides a molecular landscape of the progression of pancreatic cancer, providing new therapeutic targets to improve the prognosis of PDAC | Two yeaers |
Established Lung Cancer Cell Line and Stroma Cell From Surgical Tissue

Study Overview
=================
Brief Summary
-----------------
Try to find lung cancer stem cells from primary culture of routine surgical resection of lung cancer tissue including cancer cells and stroma cells, then characterization the established cell lines, and compare the difference of stroma cells between tumor part and surrounding part.

Official Title
-----------------
Established Lung Cancer Cell Line and Stroma Cell From Surgical Tissue: Find Lung Cancer Stem Cells and Test Its Chemotherapy Drug Resistance; Compare Stroma Cell Between Tumor Part and Surrounding Part

Conditions
-----------------
Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: lung cancer patient with surgical resection of lung tumor Exclusion Criteria: lung cancer patient without surgical resection of lung tumor

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lung cancer
Anticholinergic Risk Scale and Resource Use After Elective Noncardiac Surgery

Study Overview
=================
Brief Summary
-----------------
This study investigates the association of preoperative anticholinergic medication exposure with healthcare resource utilization in a population-based sample of older patients enrolled in a universal pharmacare program

Detailed Description
-----------------
Multilevel multivariable regression analysis will be used to investigate the adjusted association between preoperative Anticholinergic Risk Scale and postoperative healthcare resource utilization. Sensitivity analyses will be used to evaluate the robustness of the primary analysis.

Official Title
-----------------
Association of Anticholinergic Risk Scale and Healthcare Resource Use After Elective Noncardiac Surgery: a Population-based Cohort Study

Conditions
-----------------
Length of Stay, Anti Cholinergics, Surgical Procedure, Operative, Aged, Epidemiology

Intervention / Treatment
-----------------
* Other: anticholinergic risk scale


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: at least 66 years old on the day of surgery Intermediate to high risk elective noncardiac surgery Exclusion Criteria: -

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No anticholinergic exposure<br>People with an anticholinergic risk scale score of 0 | |
| Moderate anticholinergic exposure<br>People with an anticholinergic risk scale score of 1-2 | Other: anticholinergic risk scale<br>* Risk summation scale for grading and studying anticholinergic medication exposure<br>|
| High anticholinergic exposure<br>People with an anticholinergic risk scale score of >=3 | Other: anticholinergic risk scale<br>* Risk summation scale for grading and studying anticholinergic medication exposure<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hospital length of stay | Number of days in hospital after surgery | date of surgery to date of hospital discharge, or 365 days after surgery, whichever comes first | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Costs of care | Costs related to medical care paid for by the provincial health insurance system | date of surgery up to 90 days after surgery | 
| Institutional discharge | A discharge location at the end of the surgical episode of care that is not back to the patient's original residence (specifically respite or long term care) | date of surgery to date of hospital discharge, or 365 days after surgery, whichever comes first | 
| Mortality | death from any cause | from day of surgery up to 90 days after surgery | 
| Hospital readmission | Acute hospital readmission after discharge from index hospitalization | From the date of hospital discharge to 30 days after the date of discharge |
Reference Values of Cerebrospinal Fluid Outflow Resistance and Intracranial Pressure in Healthy Elderly

Study Overview
=================
Brief Summary
-----------------
Objective. The intracranial pressure and cerebrospinal outflow resistance are essential parameters to describe the cerebrospinal fluid dynamic system. Outflow resistance effects intracranial pressure, pulse amplitudes, cerebrospinal fluid absorption as well as the compliance of the system. The objective of this study was to determine the reference values in the elderly. Methods. Elderly people (60-82 years), considering themselves healthy, were recruited through an ad in the local paper. All were evaluated with a 3 Tesla magnetic resonance imaging apparatus. Subjects were eligible if they did not have any psychiatric or neurological disorder or signs of advanced atherosclerotic disease. Intracranial pressure and outflow resistance were determined by a constant pressure infusion method with the patient in the supine position. The study population consisted of 40 subjects (mean age 70 years; 23 women).

Official Title
-----------------
Reference Values of Cerebrospinal Fluid Outflow Resistance and Intracranial Pressure in Healthy Elderly

Conditions
-----------------
Healthy Elderly

Intervention / Treatment
-----------------
* Procedure: CSF dynamic investigation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy 60-82 years Exclusion Criteria: Psychiatric or neurological disorder or advanced atherosclerotic disease

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 82 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy elderly<br>Healthy elderly 60-82 years; Normal MRI; No psychiatric or neurological disorder and without signs of advanced atherosclerotic disease | Procedure: CSF dynamic investigation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CSF outflow resistance |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intracranial pressure |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intracranial pressure, resistance, CSF outflow, elderly, reference value
A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see if it is safe and effective to give delavirdine mesylate (Rescriptor) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to HIV-infected children and babies. This study also examines how the body processes Rescriptor when taken with 2 NRTIs.

Official Title
-----------------
Phase II Study of the Safety, Tolerance, Pharmacokinetics, and Antiviral Effect of Delavirdine Mesylate (Rescriptor), in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1-Infected Neonates, Infants, and Children

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Delavirdine mesylate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have: HIV infection. Plasma HIV-1 levels greater than 10,000 copies/ml.

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Delavirdine mesylate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV-1, Drug Therapy, Combination, Delavirdine, Reverse Transcriptase Inhibitors
Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare medical and surgical treatments of benign prostate hyperplasia in patients who have non muscle invasive bladder cancer for tumour recurrence and progression.

Conditions
-----------------
Bladder Cancer

Intervention / Treatment
-----------------
* Procedure: Transurethral Resection
* Drug: Tamsulosin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have non muscle invasive bladder cancer male patients patients between 40-80 years old Exclusion Criteria: Patients who have previous prostate surgery Patients who have muscle invasive bladder cancer

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: First group<br>Patients taken tamsulosin for benign prostate hyperplasia who have non muscle invasive bladder cancer | Drug: Tamsulosin<br>* Medical treatment for benign prostate hyperplasia<br>* Other names: alfa blocker treatment;|
| Active Comparator: Second Group<br>Patients taken transurethral resection prostatectomy for benign prostate hyperplasia who have non muscle invasive bladder cancer | Procedure: Transurethral Resection<br>* Endoscopic treatment of bladder cancer<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence | Bladder cancer recurrence rate | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression | Bladder cancer progression rate | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
BPH, bladder cancer, treatment, recurrence, progression